Republic of Korea-based biosimilar developer Alteogen has reported that it has been granted a process patent for its method of producing an aflibercept biosimilar, ALT-L9, referencing Regeneron’s innovator drug Eylea.
Republic of Korea-based biosimilar developer Alteogen has reported that it has been granted a process patent for its method of producing an aflibercept biosimilar, ALT-L9, referencing Regeneron’s innovator drug Eylea.
The patent describes a new, optimized process for producing the anti—vascular endothelial growth factor (anti-VEGF) fusion protein. According to Alteogen, the culture conditions of the cells that produce the proteins necessary for the biosimilar are improved through its new method, allowing for large-scale manufacturing.
In a statement announcing the new patent protection, an Alteogen representative said that “Having this patent in place, we are in the better position to fundamentally block any competitors from developing [an] Eylea biosimilar. We expect that the patent will further strengthen Alteogen’s competitiveness in Eylea biosimilar development, and Alteogen will now become a solid global first mover."
In a previous company statement, Alteogen indicated that its ALT-L9 not only showed similarity to its reference product in US-based preclinical studies but also demonstrated greater resilience to high temperatures and had a longer shelf life than the originator drug due to Alteogen’s proprietary technology.
Aflibercept is used for the treatment of eye diseases including neovascular age-related macular degeneration (AMD), diabetic macular edema, macular edema following retinal vein occlusion, and diabetic retinopathy. The brand-name product is an attractive target for biosimilar development, as it has an advantage over competitor anti-VEGF therapy ranibizumab (Lucentis); in some regulatory territories, including the European Union, aflibercept is approved for a so-called “treat-and-extend” dosing approach that reduces the number of injections and clinic visits from 12 to 4 or fewer in the second year of treatment for neovascular AMD. The lower number of intravitreal injections reduces costs and also improves patients’ treatment experience.
The reference aflibercept reached blockbuster status in the third quarter of 2018; Regeneron’s earnings results showed that a steady increase in US sales allowed the drug to bring in $1.02 billion in the United States and $1.68 billion worldwide.
At least 1 other biosimilar developer is well positioned with its biosimilar aflibercept; Momenta and Mylan, which are developing M710, entered a phase 3 pivotal trial of the biosimilar in August 2018.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.